Drug Trial News RSS Feed - Drug Trial News

MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed enrollment in a randomized Phase II clinical trial of its lead investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS). [More]
Ampio updates phase III, multicenter, double-blind STEP study of Ampion for knee osteoarthritis

Ampio updates phase III, multicenter, double-blind STEP study of Ampion for knee osteoarthritis

Ampio Pharmaceuticals, Inc. today announced an update on the phase III, multicenter, double-blind STEP study of Ampion™ for osteoarthritis of the knee. [More]
Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin toxin vaccine RiVax™, in a non-human primate (NHP) lethal aerosol exposure model. [More]
Experimental agent TRO40303 ineffective in patients with heart attack

Experimental agent TRO40303 ineffective in patients with heart attack

The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective according to results of a European study of patients with acute ST-elevation myocardial infarction (STEMI) presented today as a Hot Line the ESC Congress 2014 with simultaneous publication in the European Heart Journal. [More]
Alirocumab drug significantly improves cholesterol levels compared to ezetimibe

Alirocumab drug significantly improves cholesterol levels compared to ezetimibe

The investigational drug alirocumab significantly improved cholesterol levels compared to ezetimibe, when added to regular statin therapy in patients with high cholesterol and elevated risk of cardiovascular disease (CVD), according to the ODYSSEY COMBO II trial, presented as a Hot Line today at ESC Congress 2014. [More]
Intravenous iron supplement can improve quality of life for iron deficient heart failure patients

Intravenous iron supplement can improve quality of life for iron deficient heart failure patients

Heart failure patients with iron deficiency can experience significant and sustainable improvements in functional capacity and quality of life as well as reduced risk of hospital admission for worsening heart failure by receiving just one to two intravenous doses of an iron supplement, according to the results of a study presented today at ESC Congress 2014. [More]
Investigational LCZ696 drug: A real breakthrough for patients with heart failure

Investigational LCZ696 drug: A real breakthrough for patients with heart failure

An investigational new heart failure drug could be poised to change the face of cardiology based on Hot Line results presented today at ESC Congress 2014. [More]
Review of clinical trials based on administering antidepressants for chronic postsurgical pain

Review of clinical trials based on administering antidepressants for chronic postsurgical pain

After a systematic review of clinical trials based on administering antidepressants for acute and chronic postsurgical pain, researchers have concluded that more trials are needed to determine whether these drugs should be prescribed for postsurgical pain on a regular basis. [More]
Researchers receive encouraging results from two historic pediatric HIV vaccine trials

Researchers receive encouraging results from two historic pediatric HIV vaccine trials

Applying the benefit of hindsight, researchers at Duke Medicine have reanalyzed the findings of two historic pediatric HIV vaccine trials with encouraging results. The vaccines had in fact triggered an antibody response -- now known to be associated with protection in adults -- that was previously unrecognized in the infants studied in the 1990s. [More]
Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen Research & Development, LLC and its development partner, Bayer HealthCare, announced today the expansion of the EXPLORER global cardiovascular research program for XARELTO (rivaroxaban) to include additional high-risk patient populations. [More]
International consortium to accelerate collaborative multi-site trials of potential Ebola vaccine

International consortium to accelerate collaborative multi-site trials of potential Ebola vaccine

A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of an series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people in the current outbreak in West Africa. [More]
NIH to start initial human testing of investigational Ebola vaccine next week

NIH to start initial human testing of investigational Ebola vaccine next week

Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. [More]
TGen to lead first-in-patient clinical trial studies to test novel drugs for glioblastoma

TGen to lead first-in-patient clinical trial studies to test novel drugs for glioblastoma

SIn 2012, The Ben & Catherine Ivy Foundation awarded $10 million in grants for two groundbreaking brain cancer research projects at the Translational Genomics Research Institute. One of those projects has officially received the final regulatory approval from University of California, San Francisco, which means patient enrollment for the trial can begin. [More]
Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for evolocumab seeking approval for the treatment of high cholesterol. [More]
Isis Pharmaceuticals begins ISIS-APOCIIIRx Phase 3 study in FCS patients

Isis Pharmaceuticals begins ISIS-APOCIIIRx Phase 3 study in FCS patients

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS). FCS is a rare orphan disease, characterized by extremely high triglyceride levels, that affects an estimated 3,000 to 5,000 patients worldwide. [More]
New MS treatment found safe, tolerable in phase I clinical trials

New MS treatment found safe, tolerable in phase I clinical trials

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology Neuroimmunology & Neuroinflammation, a new online-only, freely accessible, specialty medical journal. [More]
Experimental drug shows promise as viable treatment for anemia of inflammation

Experimental drug shows promise as viable treatment for anemia of inflammation

An experimental drug designed to help regulate the blood's iron supply shows promise as a viable first treatment for anemia of inflammation, according to results from the first human study of the treatment published online today in Blood, the Journal of the American Society of Hematology. [More]
Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias Biotherapeutics Inc. has received clearance from the U.S. Food and Drug Administration to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury. [More]
Ruthigen gets DMC recommendation to begin RUT58-60 Phase 1/2 clinical trial

Ruthigen gets DMC recommendation to begin RUT58-60 Phase 1/2 clinical trial

Ruthigen Inc., a biopharmaceutical company focused on improving patient outcomes and reducing healthcare costs in invasive procedures, has announced that its lead drug candidate, RUT58-60, has received a recommendation from the Data Monitoring Committee to begin enrolling patients in the Company's planned Phase 1/2 clinical trial. [More]
Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that details from four pivotal trials in the alirocumab ODYSSEY clinical program will be presented on Sunday, August 31, during a Hot Line session at ESC Congress 2014 in Barcelona, Spain, the world's largest cardiology meeting. [More]